Swiss drug wholesaler and pharmacy operator Galenica is to cease pharmaceutical production at its subsidiary Bichsel by the end of the year, citing a lack of competitiveness. This measure will result in the loss of up to 170 jobs by the end of 2026. +Get the most important news from Switzerland in your inbox A consultation procedure is scheduled for mid-March. Galenica says it is examining "options for maintaining employment within the Group". However, if redundancies are necessary, a redundancy programme will be implemented, including financial support and professional reorientation. In future, the subsidiary will focus on homecare services, while the Grosse Apotheke Dr G. Bichsel pharmacy in Interlaken will continue to operate under the Amavita banner, the Bern-based group said in a statement on Tuesday. "Various measures aimed at improving results have not had sufficient effect in recent years," the group said, adding that it had "examined scenarios", including major investments ...
